Oddo BHF Asset Management Sas Trims Position in argenex SE $ARGX

Oddo BHF Asset Management Sas decreased its position in shares of argenex SE (NASDAQ:ARGX) by 18.7% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 23,473 shares of the company’s stock after selling 5,416 shares during the period. Oddo BHF Asset Management Sas’ holdings in argenex were worth $19,740,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. USS Investment Management Ltd lifted its stake in shares of argenex by 4.8% during the fourth quarter. USS Investment Management Ltd now owns 11,997 shares of the company’s stock valued at $10,092,000 after buying an additional 547 shares during the period. Vanguard Personalized Indexing Management LLC lifted its stake in shares of argenex by 3.8% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 3,472 shares of the company’s stock valued at $2,920,000 after buying an additional 128 shares during the period. Verition Fund Management LLC lifted its stake in shares of argenex by 527.0% during the fourth quarter. Verition Fund Management LLC now owns 2,345 shares of the company’s stock valued at $1,972,000 after buying an additional 1,971 shares during the period. Sands Capital Management LLC lifted its stake in shares of argenex by 2,046.6% during the fourth quarter. Sands Capital Management LLC now owns 356,870 shares of the company’s stock valued at $300,110,000 after buying an additional 340,245 shares during the period. Finally, Mariner LLC lifted its stake in shares of argenex by 11.0% during the fourth quarter. Mariner LLC now owns 3,754 shares of the company’s stock valued at $3,156,000 after buying an additional 371 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ARGX shares. Wedbush reissued an “outperform” rating and set a $1,000.00 price objective on shares of argenex in a research note on Thursday, June 11th. Citizens Jmp upped their price objective on shares of argenex from $925.00 to $944.00 and gave the company a “market outperform” rating in a research note on Friday, February 27th. Deutsche Bank Aktiengesellschaft raised shares of argenex from a “hold” rating to a “buy” rating in a research note on Tuesday, March 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a research report on Monday, April 20th. Finally, Wells Fargo & Company upped their price target on shares of argenex from $1,260.00 to $1,291.00 and gave the stock an “overweight” rating in a research report on Monday, June 1st. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $1,019.50.

argenex Stock Performance

Shares of ARGX stock opened at $884.20 on Tuesday. argenex SE has a one year low of $510.05 and a one year high of $934.62. The company has a 50 day moving average price of $814.84 and a 200 day moving average price of $811.27. The firm has a market capitalization of $54.99 billion, a price-to-earnings ratio of 39.37, a price-to-earnings-growth ratio of 1.37 and a beta of 0.47.

argenex (NASDAQ:ARGX) last issued its quarterly earnings results on Tuesday, March 31st. The company reported $5.52 EPS for the quarter. argenex had a net margin of 31.31% and a return on equity of 44.37%. The firm had revenue of $1.31 billion during the quarter. As a group, equities analysts forecast that argenex SE will post 26.19 EPS for the current fiscal year.

argenex Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.